Landscapes / Targets
BAFF
11 drugs act on BAFF, in 45 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs11
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Receptor molecules, native or modified |
Approved in China | Mar 2027Phase 3 trial completes | |||
| How it works | A decoy protein that soaks up a signal molecule before it can reach the body's cells | ||||
| Next date | Mar 2027 · Phase 3 trial completes | ||||
| Also tested for | Generalized Myasthenia Gravis, Primary Sjogren's Disease | ||||
| Open drug page | |||||
Belimumabnot checked |
Monoclonal antibody |
Approved | 29 Jun 2027Phase 4 trial completes | ||
| How it works | An antibody | ||||
| Next date | 29 Jun 2027 · Phase 4 trial completes | ||||
| Also tested for | Systemic Lupus Erythematosus, Systemic Sclerosis Associated Interstitial Lung Disease and 3 more | ||||
| Open drug page | |||||
Receptor molecules, native or modified |
Approved | Nov 2027Phase 2 trial completes | |||
| How it works | A decoy protein that soaks up a signal molecule before it can reach the body's cells | ||||
| Next date | Nov 2027 · Phase 2 trial completes | ||||
| Also tested for | Berger Disease, IgA Nephropathy (IgAN) and 7 more | ||||
| Open drug page | |||||
BAFF receptor (BAFF-R) antibody |
Novartis · Public NVS |
Filed | 26 Mar 2027Phase 3 trial completes | ||
| Next date | 26 Mar 2027 · Phase 3 trial completes | ||||
| Also tested for | Systemic Lupus Erythematosus, Primary Immune Thrombocytopenia (ITP) and 10 more | ||||
| Open drug page | |||||
BAFF/APRIL dual inhibitor (TACI-Fc fusion protein) |
Vertex Pharmaceuticals · Public VRTX |
Filed | 12 Dec 2027Phase 3 trial completes | ||
| Next date | 12 Dec 2027 · Phase 3 trial completes | ||||
| Also tested for | Immunoglobulin A Nephropathy, Lupus Nephritis and 4 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Phase 2 | May 2027Phase 2 trial completes | |||
| How it works | An antibody | ||||
| Next date | May 2027 · Phase 2 trial completes | ||||
| Also tested for | Systemic Sclerosis (SSc), Scleroderma and 1 more | ||||
| Open drug page | |||||
— |
Phase 2 | 31 Dec 2027Phase 2 trial completes | |||
| Next date | 31 Dec 2027 · Phase 2 trial completes | ||||
| Also tested for | Immune Thrombocytopenia (ITP), Primary Sjögren Syndrome and 1 more | ||||
| Open drug page | |||||
— |
Phase 2 | Dec 2030Phase 2 trial completes | |||
| Next date | Dec 2030 · Phase 2 trial completes | ||||
| Also tested for | Systemic Lupus Erythematosus, Non-Hodgkin Lymphoma Refractory/ Relapsed and 7 more | ||||
| Open drug page | |||||
— |
Phase 1 | 18 Nov 2026soonPhase 1 trial completes | |||
| Next date | 18 Nov 2026 · Phase 1 trial completes | ||||
| Also tested for | Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | ||||
| Open drug page | |||||
— |
Phase 1 | Jan 2027Phase 1 trial completes | |||
| Next date | Jan 2027 · Phase 1 trial completes | ||||
| Also tested for | B-cell Lymphoma | ||||
| Open drug page | |||||
— |
Phase 1 | Apr 2029Phase 1 trial completes | |||
| Next date | Apr 2029 · Phase 1 trial completes | ||||
| Also tested for | Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia and 6 more | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 10 of 11 drugs. The other 1 is marked “not checked” in the list. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026